Education
- 2016 –2017 Advanced course in “Epidemiology for clinical research”, Humanitas University, Pieve Emanuele, Milan, Italy
- 2009 –2014 Post-graduate degree in Radiation oncology, University of Florence, Faculty of Medicine and Surgery – School of Radiotherapy. Department of Radiation Oncology at Ospedale Careggi, Florence (Italy)
- 2012 –2012 Fellowship in Radiation Oncology , Royal Marsden Hospital, London (United Kingdom)
- 2002 – 2008 Degree in Medicine and Surgery. University of Naples, Faculty of Medicine and Surgery, Naples (Italy)
Academic honors, awards and prices
Best clinical presentation at Italian Association of Medical Physics Congress entitled “Phase II study of SBRT for low risk prostate cancer”. October 2014, Milan, Italy.
Other institutional appointments
- Secretary of the Italian Association of Radiotherapy (AIRO) Oligometastatic group
- Advisor of the Italian Society of Uro-oncology (SIURO) Young Session
Member of
- Italian Association of Radiotherapy (AIRO)
- Italian Association of Radiobiology (AIRB)
- European Society for Radiotherapy & Oncology (ESTRO)
- Italian Society of Uro-oncology (SIURO)
- International stereotactic radiosurgery society (ISRS)
The scientific activity of Prof Ciro Franzese focuses on the management of prostate cancer, kidney cancer and other genitourinary tumors, head and neck cancer, primary and secondary tumor of the liver, and oligometastatic disease. Prof Franzese’s research aims at the development and integration of modern radiotherapy techniques, including Stereotactic body radiation therapy (SBRT) and radiosurgery (SRS) in the multidisciplinary management of primary and metastatic disease. Moreover, his research focus on the combination of radiotherapy with modern systemic therapies, including targeted therapy and immunotherapy, and the application of artificial intelligence in radiotherapy, including radiomic and machine learning models. Prof Ciro Franzese is author and co-author of more than 160 scientific publications in international journals and book chapters. He is principal investigator of national and international prospective trials. He is also a member of different scientific societies including the Italian Association of Radiotherapy (AIRO), European Society of Radiotherapy and Oncology (ESTRO) and Italian Society of Uro-oncology (SIURO).
- The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma. Franzese C, Marini B, Baldaccini D, Badalamenti M, Navarria P, Bellu L, Franceschini D, Comito T, Clerici E, Teriaca MA, Massaro M, Di Cristina L, Lo Faro L, Tomatis S, Scorsetti M.J Cancer Res Clin Oncol. 2022 Sep 15.
- Predictive value of clinical and radiomic features for radiation therapy response in patients with lymph node-positive head and neck cancer.Franzese C, Lillo S, Cozzi L, Teriaca MA, Badalamenti M, Di Cristina L, Vernier V, Stefanini S, Dei D, Pergolizzi S, De Virgilio A, Mercante G, Spriano G, Mancosu P, Tomatis S, Scorsetti M.Head Neck. 2023 May;45(5):1184-1193.
- Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Franzese C, Comito T, Toska E, Tozzi A, Clerici E, De Rose F, Franceschini D, Navarria P, Reggiori G, Tomatis S, Scorsetti M. Radiother Oncol. 2019 Apr;133:220-226.
- Role of Stereotactic body radiation therapy in the management of oligometastatic renal cell carcinoma. Franzese C, Franceschini D, Di Brina L, D’Agostino GR, Navarria P, Comito T, Mancosu P, Tomatis S, Scorsetti M. J Urol. 2019 Jan;201(1):70-75
- The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. Franzese C, Zucali PA, Di Brina L, D’Agostino G, Navarria P, Franceschini D, Santoro A, Scorsetti M. Cancer Med. 2018 Sep;7(9):4379-4386